Contraception in Gynecologic Oncology: Pharmacologic Determinants, Thromboembolic Risk, and Tumor-Specific Clinical Selection

Contraceptive counseling in gynecologic oncology requires integration of medical eligibility, contraceptive pharmacology, tumor characteristics, and treatment status. This narrative review synthesizes professional guidance and selected clinical, epidemiologic, and mechanistic literature, distinguishing direct post-diagnosis contraceptive outcomes from indirect evidence. General-population studies associate combined oral contraception with increased venous thromboembolism (VTE), with differences between formulations; most progestin-only pills, implants, and levonorgestrel intrauterine systems show no consistent increase, whereas depot medroxyprogesterone acetate has a VTE signal. These estimates do not quantify formulation-specific risk in patients with gynecologic cancer. Histotype and endocrine treatment warrant particular attention in low-grade serous and endometrioid ovarian carcinomas, adult granulosa cell tumors, and low-grade endometrial stromal sarcoma. Molecular prognostic markers have not been validated as predictors of contraceptive effects on recurrence or survival. A qualitative framework, an annotated method-selection table, and a decision pathway organize formulation, host, tumor, treatment, and procedural considerations, including perimenopausal use and regional prescribing differences. The framework is an author-derived synthesis rather than a validated prediction model, evidence-grading system, or medical eligibility classification. It is intended to support individualized, multidisciplinary counseling alongside established recommendations. Prospective studies of post-diagnosis exposure, recurrence, survival, and vascular outcomes are needed before its clinical utility can be established.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2026-11-18
DOI
https://doi.org/10.3390/cancers18223695
Primary Topic
Reproductive Health and Contraception
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Contraception in Gynecologic Oncology: Pharmacologic Determinants, Thromboembolic Risk, and Tumor-Specific Clinical Selection

Dimitrios‐Efthymios Vlachos, Nikolaos Thomakos, Antonia Varthaliti, Chrysi Christodoulaki et al.
1 links
Cancers
Reproductive Health and Contraception
article

Contraception in Gynecologic Oncology: Pharmacologic Determinants, Thromboembolic Risk, and Tumor-Specific Clinical Selection

Dimitrios‐Efthymios Vlachos, Nikolaos Thomakos, Antonia Varthaliti, Chrysi Christodoulaki, Γεωργία Μπουντουράκη, Vasilios Lygizos, Dimitris Baroutis, G. Daskalakis, Periklis Panagopoulos, Rafaela Panagopoulou, Vasilios Pergialiotis
article en

Abstract

Contraceptive counseling in gynecologic oncology requires integration of medical eligibility, contraceptive pharmacology, tumor characteristics, and treatment status. This narrative review synthesizes professional guidance and selected clinical, epidemiologic, and mechanistic literature, distinguishing direct post-diagnosis contraceptive outcomes from indirect evidence. General-population studies associate combined oral contraception with increased venous thromboembolism (VTE), with differences between formulations; most progestin-only pills, implants, and levonorgestrel intrauterine systems show no consistent increase, whereas depot medroxyprogesterone acetate has a VTE signal. These estimates do not quantify formulation-specific risk in patients with gynecologic cancer. Histotype and endocrine treatment warrant particular attention in low-grade serous and endometrioid ovarian carcinomas, adult granulosa cell tumors, and low-grade endometrial stromal sarcoma. Molecular prognostic markers have not been validated as predictors of contraceptive effects on recurrence or survival. A qualitative framework, an annotated method-selection table, and a decision pathway organize formulation, host, tumor, treatment, and procedural considerations, including perimenopausal use and regional prescribing differences. The framework is an author-derived synthesis rather than a validated prediction model, evidence-grading system, or medical eligibility classification. It is intended to support individualized, multidisciplinary counseling alongside established recommendations. Prospective studies of post-diagnosis exposure, recurrence, survival, and vascular outcomes are needed before its clinical utility can be established.

CancersVol. 18(22)
National and Kapodistrian University of Athens (GR), Alexandra Hospital (GR), Chania General Hospital ”St. George” (GR), University General Hospital Attikon (GR)
Good health and well-being
Reproductive Health and Contraception
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon